Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI-001 in Iron Deficiency and Hereditary Hemochromatosis
NCT05238207Phase 1Terminated
- Sponsor
- Bond Biosciences
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BBI-001 in hereditary hemochromatosis (HH) (2 arms), sponsored by Bond Biosciences. Primary endpoints: Adverse Events at 17 days and Clinical Laboratory Testing - Iron Panel at 17 days. Started Mar 2022; status: terminated.
02
Drugs
BBI-001
03
Conditions
hereditary hemochromatosis (HH)
Beyond the preview
Go deeper on NCT05238207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238207.